Etravirine Resistance: Baseline Prevalence and Proposed Criteria for “Vircotype”

Data presented at the 15th Retrovirus Conference shed light on which patients will be appropriate candidates for etravirine treatment.

Etravirine, recently approved by the FDA for treatment-experienced patients, is the first NNRTI that can be used after treatment failure and resistance with other NNRTIs (ACC Jan 28 2008). At the 15th Retrovirus Conference, several groups reported on the proportion of clinical isolates that are likely to have etravirine resistance, defined as the presence of three or more etravirine-related mutations. In studies from diverse locations — Spain, Nigeria, and Thailand — and from Virco (a resistance laboratory owned by the same parent corporation that makes etravirine), the proportion of NNRTI-resistant viruses with etravirine resistance varied from 7% to 30%, with the highest rate being in Thailand [Abstracts 865, 866, 867, and 868]. One poten…

Author

Paul E. Sax, MD

Disclosures

Consultant/Advisory BoardGilead Sciences; GlaxoSmithKline/ViiV; Merck; Shionogi

Grant/Research SupportNIH; Gilead Sciences; ViiV

Editorial BoardsUpToDate; Clinical Infectious Diseases

Paul E. Sax, MD

Disclosures

Consultant/Advisory BoardGilead Sciences; GlaxoSmithKline/ViiV; Merck; Shionogi

Grant/Research SupportNIH; Gilead Sciences; ViiV

Editorial BoardsUpToDate; Clinical Infectious Diseases

Etravirine Resistance: Baseline Prevalence and Proposed Criteria for “Vircotype”

Topics

Author